Immuneering Corp • IMRX

Capital at risk.

About Immuneering Corp
Ticker
info
IMRX
Trading on
info
NASDAQ
ISIN
info
US45254E1073
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Headquarters
info
245 Main Street, Cambridge, MA, United States, 02142
Employees
info
54
Website
info
https://immuneering.com
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Metrics
BasicAdvanced
Market cap
info
$435M
P/E ratio
info
-
EPS
info
-$1.79
Dividend Yield
info
0.00%
Beta
info
0.46
Forward P/E ratio
info
0
EBIDTA
info
$-63.8M
Ex dividend date
info
-
Price & volume
Market cap
info
$435M
Average daily volume
info
1.1M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
563.62
Price to book
info
1.91
Earnings
EPS
info
-$1.79
EPS estimate (current quarter)
info
-$0.39
EPS estimate (next quarter)
info
-$0.38
EBITDA
info
$-63.8M
Revenues (TTM)
info
$0M
Revenues per share (TTM)
info
$0.00
Technicals
Beta
info
0.46
52-week High
info
$10.08
52-week Low
info
$1.10
50-day moving average
info
$6.67
200-day moving average
info
$3.87
Short ratio
info
5.93
Short %
info
13.70%
Management effectiveness
ROE (TTM)
info
-43.75%
ROA (TTM)
info
-25.91%
Profit margin
info
0.00%
Gross profit margin
info
$0.2M
Operating margin
info
0.00%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
-99.80%
Share stats
Outstanding Shares
info
64.6M
Float
info
45.3M
Insiders %
info
17.82%
Institutions %
info
48.39%
Analyst Insights & forecasts
info

80% Buy

20% Hold

0% Sell

Based on information from 5 analysts.

Average price target

info
$16.83
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$1.07
-$0.45
-137.78%
Q4 • 24Missed
-$0.44
-$0.49
10.20%
Q1 • 25Beat
-$0.82
-$0.42
-95.24%
Q2 • 25Missed
-$0.38
-$0.41
7.32%
Q3 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$-14.4M
-∞%
Q2 • 25
$0M
$-15M
-∞%
Q3 • 25
NaN%
3.68%
NaN%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$40.1M
$11.1M
27.76%
Q2 • 25
$241M
$13.1M
5.43%
Q3 • 25
501.79%
17.62%
-80.46%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-9.4M
$-0M
$-0.1M
$-9.4M
Q2 • 25
$-12M
$-0M
$213M
$-12M
Q3 • 25
26.80%
242.86%
-344,191.27%
26.84%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Immuneering Corp share?
Collapse

Immuneering Corp shares are currently traded for undefined per share.

How many shares does Immuneering Corp have?
Collapse

Immuneering Corp currently has 64.6M shares.

Does Immuneering Corp pay dividends?
Collapse

No, Immuneering Corp doesn't pay dividends.

What is Immuneering Corp 52 week high?
Collapse

Immuneering Corp 52 week high is $10.08.

What is Immuneering Corp 52 week low?
Collapse

Immuneering Corp 52 week low is $1.10.

What is the 200-day moving average of Immuneering Corp?
Collapse

Immuneering Corp 200-day moving average is $3.87.

Who is Immuneering Corp CEO?
Collapse

The CEO of Immuneering Corp is Dr. Benjamin J. Zeskind M.B.A., Ph.D..

How many employees Immuneering Corp has?
Collapse

Immuneering Corp has 54 employees.

What is the market cap of Immuneering Corp?
Collapse

The market cap of Immuneering Corp is $435M.

What is the P/E of Immuneering Corp?
Collapse

The current P/E of Immuneering Corp is null.

What is the EPS of Immuneering Corp?
Collapse

The EPS of Immuneering Corp is -$1.79.

What is the PEG Ratio of Immuneering Corp?
Collapse

The PEG Ratio of Immuneering Corp is null.

What do analysts say about Immuneering Corp?
Collapse

According to the analysts Immuneering Corp is considered a buy.